Tanke Biosciences Corporation
Tanke Biosciences Corporation, through its subsidiary, Best Energy Monitoring LLC, engages in the energy monitoring business. The company monitors and analyses accurate, itemized, and real-time energy data. Its assets are utilized in the monitoring of energy consumption using internet of things (IoT), big data, and artificial intelligence for commercial buildings, such as food retail, quick servi… Read more
Tanke Biosciences Corporation (TNBI) - Total Liabilities
Latest total liabilities as of June 2025: $390.71K USD
Based on the latest financial reports, Tanke Biosciences Corporation (TNBI) has total liabilities worth $390.71K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tanke Biosciences Corporation - Total Liabilities Trend (2007–2024)
This chart illustrates how Tanke Biosciences Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tanke Biosciences Corporation Competitors by Total Liabilities
The table below lists competitors of Tanke Biosciences Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Intergama
TA:INTR
|
Israel | ILA26.66 Million |
|
BERKELEY GRP - Dusseldorf Stock Exchang
DU:42BA
|
Germany | €3.44 Billion |
|
Hiru Corporation
PINK:HIRU
|
USA | $8.40 Million |
|
Allied Resources Inc
PINK:ALOD
|
USA | $526.55K |
|
OMEGA HLTH INV REIT (WX4.SG)
STU:WX4
|
Germany | €5.17 Billion |
|
OneApex Limited
F:CWF
|
Germany | €281.00K |
|
Canoo Holdings Ltd
NASDAQ:GOEVW
|
USA | $301.33 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Tanke Biosciences Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tanke Biosciences Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tanke Biosciences Corporation (2007–2024)
The table below shows the annual total liabilities of Tanke Biosciences Corporation from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $248.86K | +51.00% |
| 2023-12-31 | $164.81K | +72.66% |
| 2022-12-31 | $95.45K | -5.94% |
| 2021-12-31 | $101.48K | -99.21% |
| 2012-12-31 | $12.93 Million | +43.10% |
| 2011-12-31 | $9.03 Million | +16003.66% |
| 2010-12-31 | $56.09K | +74.06% |
| 2009-12-31 | $32.23K | +86.16% |
| 2008-12-31 | $17.31K | +328.17% |
| 2007-12-31 | $4.04K | -- |